The Institute of Bioorganic Chemistry offers consumers a medicinal product - the antitumor drug Bortezomib on the basis of a manufacturing agreement, a technology for obtaining a substance on the basis of a license agreement, and is looking for partners to conclude a distribution services agreement.

Lyophilized powder for the preparation of a solution for intravenous and subcutaneous administration, 3.5 mg and 2.0 mg.

The antitumor agent Bortezomib is used to treat multiple myeloma and mantle cell lymphoma in patients who have previously received at least one line of therapy.

The technology of production of pharmaceutical substance and dosage form of the drug Bortezomib, regulatory and technical documentation has been developed. The pharmaceutical substance Bortezomib was registered (FSP RB 2136-15; RU No. 15/07/2421 of 07/30/2015). Clinical trials of the drug Bortezomib have been carried out.

The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents, and pesticides to manufacturers.

Consumers interested in purchasing the anticancer drug Bortezomib under a manufacturing agreement.

Distributors interested in purchasing the anticancer drug Bortezomib under a distribution services agreement.

Partners interested in acquiring technology for obtaining the substance of the anticancer drug Bortezomib under a license agreement.